Drug development for metastatic castration-resistant prostate cancer: current status and future perspectives.

@article{Lassi2011DrugDF,
  title={Drug development for metastatic castration-resistant prostate cancer: current status and future perspectives.},
  author={Kiran Lassi and Nancy Ann Dawson},
  journal={Future oncology},
  year={2011},
  volume={7 4},
  pages={551-8}
}
Prostate cancer represents a third of all newly diagnosed cancers in men in the USA with an estimated incidence of 192,280 cases and 27,360 deaths in 2009. It continues to be a major cause of cancer-related morbidity and mortality, and there is an urgent need for new treatments. Historically, systemic therapy options were limited after progression on docetaxel-based chemotherapy. This article reviews current data on the novel therapeutics demonstrating activity in metastatic castration… CONTINUE READING
5 Citations
32 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 32 references

A randomized , multicenter , international Phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate - resistant prostate cancer ( CRPC )

  • R Pili, M Haggman, WM Stadler
  • J . Clin . Oncol .
  • 2010

A randomized Phase II study of OGX - 011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer

  • KN Chi, SJ Hotte, EY Yu
  • J . Clin . Oncol .
  • 2010

Delaying skeletal related events in a randomized Phase III study of denosumab versus zolendronic acid in patients with advanced cancer

  • DH Henry, R vonMoos, V Hungria
  • J . Clin . Oncol .
  • 2010

Periman PO , Bernold D et al . : Sutinib malate for metastatic castration - resistant prostate cancer after docetaxel based chemotherapy

  • G Sonpavde
  • Ann . Oncol .
  • 2010

Similar Papers

Loading similar papers…